We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s Calquence Approved in Europe for Chronic Lymphocytic Leukemia
AstraZeneca’s Calquence Approved in Europe for Chronic Lymphocytic Leukemia
The European Commission has approved AstraZeneca’s leukemia drug Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL).